0000899243-17-015164.txt : 20170602 0000899243-17-015164.hdr.sgml : 20170602 20170602163029 ACCESSION NUMBER: 0000899243-17-015164 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170531 FILED AS OF DATE: 20170602 DATE AS OF CHANGE: 20170602 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: AESCHENVORSTADT 36 CITY: BASEL STATE: V8 ZIP: 4051 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: AESCHENVORSTADT 36 CITY: BASEL STATE: V8 ZIP: 4051 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bolzon Bradley J PhD CENTRAL INDEX KEY: 0001354345 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 17888360 MAIL ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-05-31 0 0001674416 CRISPR Therapeutics AG CRSP 0001354345 Bolzon Bradley J PhD C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 1 0 0 0 Stock Option (Right to Buy) 13.62 2017-05-31 4 A 0 30000 0.00 A 2027-05-31 Common Shares 30000 30000 I See Footnote These options were granted on May 31, 2017 with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017. One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Thomas Woiwode, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. /s/ Michael Esposito, attorney-in-fact 2017-06-02